SML2731
alpha-NETA
≥98% (HPLC), ChAT inhibitor, powder
别名:
α-NETA, 2-(alpha-Naphthoyl)ethyltrimethylammonium iodide, N,N,N-Trimethyl-γ-oxo-1-naphthalenepropanaminium iodide, N,N,N-Trimethyl-3-(naphthalen-1-yl)-3-oxopropan-1-aminium iodide, a-NETA
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C16H20INO
化学文摘社编号:
分子量:
369.24
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
alpha-NETA, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C(C1=CC=CC2=C1C=CC=C2)CC[N+](C)(C)C.[I-]
InChI
1S/C16H20NO.HI/c1-17(2,3)12-11-16(18)15-10-6-8-13-7-4-5-9-14(13)15;/h4-10H,11-12H2,1-3H3;1H/q+1;/p-1
InChI key
QZXMJYVXMZJOAO-UHFFFAOYSA-M
Biochem/physiol Actions
Originally identified as a substrate (ChA or choline)-noncompetitive, slowly reversible choline acetyltransferase inhibitor (human ChAT/BuChE/AChE IC50 = 88 nM/33.3 μM/48.6 μM; does not affect mAChRs, AChE, ChE, CrAT, ganglionic or skeletal muscular nAChRs), α-NETA is a fluorescent molecule (Ex 255 & 297 nm; Em 427 nm) also known for its trace amine-associated receptor 5 (TAAR5 EC50 = 150 nM) agonist and chemokine-like receptor-1 antagonist (IC50 = 375 nM; 7 nM chemerin-induced CMKLR1 β-ARR2 recruitment) potencies both in cultures and in animal disease models in vivo (3-20 mg/kg via ip. or sc. in rats & mice).
Potent ChAT inhibitor, TAAR5 agonist, CMKLR1 (ChemR23) antagonist with in vivo efficacies in animal disease models.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Justine M Abais-Battad et al.
Hypertension (Dallas, Tex. : 1979), 73(2), 440-448 (2019-01-01)
Studies from our laboratory have revealed an important role for the maternal diet and the dietary protein source in the development of hypertension and renal injury in Dahl salt-sensitive (SS) rats. The current study sought to compare salt-induced hypertension, renal
Vineet Kumar et al.
Scientific reports, 9(1), 7178-7178 (2019-05-11)
Small molecules that disrupt leukocyte trafficking have proven effective in treating patients with multiple sclerosis (MS). We previously reported that chemerin receptor chemokine-like receptor 1 (CMKLR1) is required for maximal clinical and histological experimental autoimmune encephalomyelitis (EAE); and identified CMKLR1
Kareem L Graham et al.
PloS one, 9(12), e112925-e112925 (2014-12-02)
Therapies that target leukocyte trafficking pathways can reduce disease activity and improve clinical outcomes in multiple sclerosis (MS). Experimental autoimmune encephalomyelitis (EAE) is a widely studied animal model that shares many clinical and histological features with MS. Chemokine-like receptor-1 (CMKLR1)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2731-5MG | 04061841290216 |
| SML2731-25MG | 04061841290209 |